PFIZER LIMITED Pfizer Limited revenues (on a like to like basis) increases by 12% for the year ended March 31, 2015.
Results not comparable as the effect for amalgamation has been
given during the year ended March 31, 2015
Pfizer Ltd announced its audited results for the year ended March 31, 2015.
Amalgamation of Wyeth Ltd
The Scheme of Amalgamation of Wyeth Ltd with Pfizer Ltd had become effective
on December 01, 2014 ("Effective Date"). The appointed date is April 1, 2013. The
effect of amalgamation has been given in the results for the current quarter,
sequential quarter and the year ended March 31, 2015. The results are not
strictly comparable as the previous year quarter and year end are standalone
Pfizer Ltd results.
Revenues
A like to like comparison, reflects revenue of ` 1828 crore for the year ending
March 31, 2015 as compared to ` 1632 crore for the same period last year,
reflecting a growth of 12%.
Profits before other income, exceptional items and tax
Profit from operations (before other income, exceptional items and tax) for
the year is ` 252crore.
EBITDA for the year is at 21%.
Higher expenses and depreciation / amortization arising on amalgamation
have impacted the profit from operations for the year.
Excluding one off / incremental expenses, the EBITDA would be at 24%.
Exceptional items
The company had announced a voluntary retirement scheme during the year
in its Plant at Thane. Expenses in relation to VRS and other related costs are
reflected as Exceptional item.
Profit after tax
Profit after tax has been impacted by comparatively lower bank interest income
and higher expenses. The profit is further impacted by depreciation / amortization
on assets (goodwill, intangibles and tangible) arising out of amalgamation amounts
to ` 118 crore for the financial year 2013-14 and 2014-15 respectively. Profit for the
year after the impact of amalgamation is ` 70crore.
Dividend
The Board has recommended dividend of ` 12.5 per equity share of ` 10 each (125%)
during the financial year ended March 31, 2015.
Contacts -
Investors: Media:
Prajeet Nair Harsh Sheth / Samantha D'Souza
Pfizer Ltd MSL Group
Ph: +91-22-66932352 Ph: +91-9870631557 / +91-9920238249
About Pfizer Ltd:
well-being at every stage of life. We strive to set the standard for quality,
safety and value in the discovery, development and manufacturing of
medicines for people. Every day, Pfizer colleagues work to advance wellness,
prevention, treatments and cures that challenge the most feared diseases of
our time. Consistent with our responsibility as the world's leading
biopharmaceutical company, we also collaborate with health care providers,
governments and local communities to support and expand access to reliable,
affordable health care around the world. For more than 60 years in India, Pfizer has
worked to make a difference for all who rely on us. To learn more about our
commitments, please visit us at www.pfizerindia.com
Disclaimer
All actions and statements made herein or otherwise shall be subject to the
applicable laws and regulations as amended from time to time. There is no
representation that all information relating to the context has been taken
care of in the press release and neither we undertake any obligation as to
the regular updating of the information as a result of new information,
future events or otherwise. We will accept no liability whatsoever for any
loss arising directly or indirectly from the use of, reliance of any information
contained in this press release or for any omission of the information. The
information shall not be distributed or used by any person or entity in any
jurisdiction or countries were such distribution or use would be contrary to
the applicable laws or Regulations. It is advised that prior to acting upon
this press release, independent consultation / advise may be obtained
and necessary due diligence, investigation etc. may be done at your end.
|
distributed by
|
